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Summary: We developed an enzyme immunoassay (ELISA) for quantitation of plasma cholinesterase substance
concentrations in native plasma or serum samples. The ELISA assay is based on polyclonal (rabbit) anti-
human cholinesterase and a highly specific monoclonal (mouse) antibody, with a commercially available
peroxidase-conjungated (rabbit) antibody directed against mouse immunoglobulins as the signal carrier. The
detected serum cholinesterase substance concentrations (mean: 4.51 mg/1, SD: 0.90 mg/1) in randomly selected




acylhydrolase, EC 3.1.1.8), which is biosynthesized in
the liver, occurs in plasma as a number of distinct
isozymes (1—4), but predominantly as a globular,
tetrameric structure with a relative molecular mass of
340 000 (5). Cholinesterase is eliminated from plasma
with a half-life of 5 — 12 days (3). Catalytic activity
concentrations of plasma cholinesterase are influ-
enced by a variety of physiological and pathological
conditions (2, 3, 6 — 8); further, a great number of
chemicals, e.g. carbamates and organophosphorus
compounds (systemic insecticides), are potent inhibi-
tors (2, 3). Even in healthy, unexposed individuals,
substantial intra-individual variations occur (8, 9). A
wide variety of sensitive and precise analytical tech-
l) The study was financially supported by the Aarhus Univer-
sity Research Foundation.
niques for measuring catalytic plasma cholinesterase
activity concentration have been available for many
years (for reviews, see Augustinusson (10), and Silk et
al. (11)). In order to interpret the observed variations
of plasma cholinesterase catalytic activity, it is im-
portant to determine whether a decreased catalytic
activity is the result of a reduced cholinesterase sub-
stance concentration (e. g. due to reduced synthesis),
or a partial inhibition of the catalytic activity (e. g.
due to exposure to systemic insecticides). Information
on cholinesterase substance concentrations in native
plasma samples is quite scanty (12 — 16), and previ-
ously published methods for the quantitation of
plasma cholinesterase substance concentration are la-
borious and unsuited for large series of samples. In
the present paper we describe an easy, but highly
reliable enzyme immunoassay for the determination
of plasma cholinesterase substance concentration and
its application to randomly selected blood samples
from healthy individuals.
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Materials and Methods
Catalytic activity
Plasma cholinesterase catalytic activity concentrations were
measured at 37 °C, using butyrylthiocholine as substrate (8);
reference values for healthy individuals, mean: 8.45 kU/1, SD:
1.94kU/l.
Enzyme l inked immuno sorbent assay
Procedure
Each well of a microtitre plate (Maxisorp 473709, Nunc, Kam-
strup, Roskilde, Denmark) was coated overnight with 100 μΐ
polyclonal rabbit antibodies against human plasma cholineste-
rase (Statens Seruminstitut, Copenhagen, Denmark), diluted
1:5000 in 0.1 mol/1 carbonate buffer pH 9.6, then washed with
300 μΐ phosphate-buffered saline containing 1 mol/1 Tween 20
(Merck 822184), pH 7.O.
When running the assay, 100 μΐ of sample or calibrator (Stand-
ard Human Serum, lot no. A041022F, Behringwerke, Marburg,
FRG, containnig 5.5 mg/1 immunoreactive cholinesterase, see
below), prediluted 1:400 (samples) or 1 :300-1 :1500 (calibra-
tor), was incubated at room temperature for 2 hours. After
washing, 100 μΐ monoclonal (mouse) anti-human plasma cho-
linesterase (cell line HAH 2-1, Statens Seruminstitut, Copen-
hagen, Denmark), diluted 1:500 in phosphate-buffered saline
with 1 ml/1 Tween 20, was added and incubated at room tem-
perature for another hour. After a further washing step, the
monoclonal mouse antibody was detected by a horse radish
peroxidase-conjugated (rabbit) antibody against mouse IgG
(P260, Dakopatts, Glostrup, Denmark), diluted 1:1000. Per-
oxidase activity was determined by a conventional end-point
reaction using o-phenylenediamine as substrate (17). Absorb-
ance was read at 490 nm.
The dose-response curve is shown in figure 1. All samples and
calibrators were run in duplicate; within assay precision esti-
mated from the deviations of duplicates: CV = 1.36%
(N = 33). Coated microtitre plates were found to be uninflu-
enced by storage at 4 °C for at least one week. Under the
described conditions, prediluted native serum samples exhibited
immunoreactive cholinesterase substance concentrations which
were directly proportional to the volume of sample applied.
Calibration
For final calibration, we prepared a highly purified human
cholinesterase, which was quantitated according to Lowry et
al. (18); the preparation showed one homogenous protein frac-
tion in SDS polyacrylamide gel electrophoresis.
Cholinesterase from 100 ml plasma was adsorbed by immu-
noaffinity chromatography, using a monoclonal antibody
against human plasma cholinesterase (cell line HAH 2-1, pro-
tein A purified IgG, Statens Seruminstitut, Copenhagen, Den-
mark) coupled (3.6 g IgG per litre gel) to CNBr-activated Se-
pharose 4B (Pharmacia-LKB, Uppsala, Sweden). Cholinester-
ase was desorbed with TRIS-buffered 4.5 mol/1 MgCl2, pH 7.5,
and further purified by FPLC on a Mono Q HR 5/5 column
(Pharmacia-LKB, Uppsala, Sweden), using a linear salt gra-
dient of ammonium acetate (0.05—0.50 mol/1, pH 8.0). Using
bovine serum albumin (Sigma A-4503, lot no. 98F-0047) 50
mg/1 in 0.28 mol/1 ammonium acetate (same as the fractions
containing cholinesterase) as reference, the protein concentra-
tion of the purified cholinesterase was determined to be 33 mg/1
(18). Based on this protein concentration and the immunoreac-
tivity of the purified cholinesterase, the immunoreactive cholin-
esterase substance concentration of the daily calibration ma-
terial (Standard Human Serum, lot. no. A041022F, Behring-
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Fig. 1. Enzyme immunoassay of human plasma cholinesterase:
calibration curve.
Specificity
The specificity of the monoclonal anti-human plasma cholin-
esterase antibody, HAH 2-1, was assessed by crossed immu-
noelectrophoresis (19), stained for catalytic cholinesterase ac-
tivity, and examined for immunoreactive cholinesterase. The
monoclonal antibody HAH 2-1 reacted exclusively with the
immuno-precipitate possessing catalytic cholinesterase activity
(fig. 2). In gel filtration experiments (Sephacryl S-300, Phar-
macia-LKB, Uppsala, Sweden) all fractions with catalytic cho-
linesterase activity showed immunoreactive cholinesterase sub-
stance concentrations corresponding to a uniform specific cat-
alytic activity of 1.2 — 1.3 kU/mg (fig. 3). Only fractions con-
taining cholinesterase catalytic activity were detected by the
ELISA assay.
Fig. 2. Serum proteins separated by crossed immunoelectro-
phoresis, with non-specific, polyclonal rabbit antibodies
against human plasma cholinesterase in the gel used for
2nd dimension.
(a) gel stained specifically for catalytic cholinesterase
activity (a-naphthyl acetate/Fast Red TR).
(b) gel stained for HAH 2-1 immunoreactive cholines-
terase by a peroxidase-conjungated rabbit antibody
against mouse immunoglobulins (19).
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Fig. 3. Catalytic cholinesterase activity concentration (open cir-
cles) and immunoreactive cholinesterase substance con-
centration (filled circles) in plasma fractions separated
by gel filtration (Sephacryl S-300, column: 60 χ 1.6 cm,
sample: 4 ml, flow: 5 ml h"1).
Two plasma proteins, acetylcholinesterase (EC 3.1.1.7) and
thyroglobulin, contain homologous amino acid sequences with
cholinesterase (5, 20, 21). When estimated by an established
enzyme antigen immunoassay (22), acetylcholinesterase in nor-
mal human plasma occurs in concentrations corresponding to
about 3 U/l. Purified red blood cell acetylcholinesterase (23) in
an excess concentration (19.2 kU/1 (22)), or serum acetylcholin-
esterase in a 10-fold concentration (32 U/l) showed no inter-
ference in the ELISA assay (AAacetylcholinesterase: 0.012; AAblank:
0.011). A 100-fold concentration (5mg/l) of thyroglobulin also
showed no interference (AAthyroglobuiin· 0.028; AAbIank: 0.028).
Results and Discussion
The relation between cholinesterase catalytic activity
concentration and immunoreactive cholinesterase
substance concentration in randomly selected, freshly
drawn serum samples from 33 healthy individuals
(blood donors) is shown in figure 4. The figure shows
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Fig. 4. Relation between catalytic cholinesterase activity con-
centration and immunoreactive cholinesterase substance
concentration in random serum samples from 33 indi-
viduals; y = 1.74 χ + 0.40 (r2 = 0.90, SDslope: 0.11,
SDintercept: 0.49).
tive substance concentration and catalytic activity
concentration, without a significant ordinate intercept
(t = 0.82); mean specific catalytic activity: 1.74 kU/
mg, SD: 0.11 mg/l; mean catalytic cholinesterase ac-
tivity concentration: 8.28 kU/1, SD: 1.66 U/l; mean
immunoreactive substance concentration: 4.51 mg/l,
SD: 0.90 mg/l.
A number of earlier studies (13 — 16), reported native
plasma cholinesterase substance concentrations of
5 — 15 mg/l; however, this consensus is not surprising
since all studies (performed by crossed immunoelec-
trophoresis (13, 14) or rockets (15, 16)) were based
on the same polyclonal antibody (A 032, Dakopatts,
Glostrup, Denmark), and the same calibration ma-
terial (Standard Human Serum Op. No. 166, Beh-
ringwerke, FRG). With a mean catalytic activity con-
centration of 8.45 kU/1 (8), this substance concentra-
tion corresponds to a specific catalytic activity of
about 0.8 kU/mg.
In their study of purified human plasma cholinester-
ase, Lockridge & La Du (24) found a specific catalytic
activity of 170 U/mg, measuring the catalytic activity
according to Kalow & Lindsay (25) with benzoylcho-
line as the substrate. Recalculation of this specific
catalytic value, using published reference values (ben-
zoylcholine at 25 °C: 0.65-1.45 kU/1 (3); butyryl-
thiocholine at 37 °C: 8.45 ± 1.94 kU/1 (8)), gives a
value of about 1.4 kU/mg for the conditions used in
our study.
In the present study, we find a mean specific catalytic
cholinesterase activity in native serum samples of 1.74
kU/mg (SD: 0.11 kU/mg), which is about twice the
specific catalytic activity previously reported (13 —
16), and substantially higher than that reported for
the purified enzyme (24). Such a high specific catalytic
activity of plasma cholinesterase might be explained
by
1., a previously overestimated cholinesterase sub-
stance concentration, e. g. due to interference by other
proteins;
2., in agreement with our observations (fig. 3), a
decreased catalytic cholinesterase activity of purified
cholinesterase; or,
3., an underestimation of the purified cholinesterase
substance concentration used for the final calibration
of the ELISA described here.
We based our protein quantitation of the highly pur-
ified cholinesterase on the classical Polin reaction (as
modified by Lowry et al. (18)) using a well character-
ized, pure bovine serum albumin (in the same buffer
as the purified cholinesterase) as reference. A lower
content of phenolic amino acids in cholinesterase
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would tend towards an underestimation of the protein
mass concentration. However, the content of tyrosine
(20 tyrosyl in 574 residues (21)) in cholinesterase is
similar to that of bovine serum albumin (19 tyrosyl
in 581 residues (26)), and cholinesterase even has a
higher content of tryptophan (18 residues) than bo-
vine serum albumin (2 residues). As a result, sugges-
tions of an underestimation of the cholinesterase pro-
tein mass concentration used for final calibration of
the ELISA can be rejected.
The enzyme immunoassay presented here allows a
precise quantitation of immunoreactive cholinesterase
substance concentration in native serum or plasma
samples. The immunoassay has the following four
important characteristics.
1. It is based on a monoclonal antibody without
detectable cross reactivity with other serum proteins
(fig-2).
2. Partially homologous proteins do not interfere sig-
nificantly.
3. All fractions obtained by gel filtration which exhibit
catalytic cholinesterase activity show parallel immu-
noreactivity (fig. 3).
4. The catalytic activity concentration is closely and
linearly related to immunoreactive cholinesterase sub-
stance concentration (fig.4).
It can therefore be concluded that the immunoassay
described here is a reliable method for specific, and
valid quantitation of immunoreactive native plasma
cholinesterase substance concentrations.
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